Journal: Biochemistry and Biophysics Reports

Article Title: Oxidative impact on lipoprotein structure: Insights from dynamic light scattering

doi: 10.1016/j.bbrep.2025.101945

Figure Lengend Snippet: Chemical information of lipoprotein standards (Lee Biosolutions).

Article Snippet: Commercial HDL (Cat No. 361-10, Lot Number 12C1847), LDL (Cat No. 360-10, Lot Number 03C1863), and VLDL (Cat No. 365-10, Lot Number 11C1054) standards were purchased from Lee Biosolutions.

Techniques:

Journal: Biochemistry and Biophysics Reports

Article Title: Oxidative impact on lipoprotein structure: Insights from dynamic light scattering

doi: 10.1016/j.bbrep.2025.101945

Figure Lengend Snippet: Absorbance at 234 nm ± CV following 24-h incubation at 37 °C.

Article Snippet: Commercial HDL (Cat No. 361-10, Lot Number 12C1847), LDL (Cat No. 360-10, Lot Number 03C1863), and VLDL (Cat No. 365-10, Lot Number 11C1054) standards were purchased from Lee Biosolutions.

Techniques: Incubation, Control, Nitration

Journal: Biochemistry and Biophysics Reports

Article Title: Oxidative impact on lipoprotein structure: Insights from dynamic light scattering

doi: 10.1016/j.bbrep.2025.101945

Figure Lengend Snippet: Estimation of MDA (μM) ± CV measured by TBARS Assay at 0- and 24-h Incubation at 37 °C.

Article Snippet: Commercial HDL (Cat No. 361-10, Lot Number 12C1847), LDL (Cat No. 360-10, Lot Number 03C1863), and VLDL (Cat No. 365-10, Lot Number 11C1054) standards were purchased from Lee Biosolutions.

Techniques: TBARS Assay, Incubation, Control, Nitration

Journal: Biochemistry and Biophysics Reports

Article Title: Oxidative impact on lipoprotein structure: Insights from dynamic light scattering

doi: 10.1016/j.bbrep.2025.101945

Figure Lengend Snippet: Overlay of volume PSDs measured by DLS for clinical sample lipoprotein fractions: HDL (red), LDL (green), and VLDL (blue).

Article Snippet: Commercial HDL (Cat No. 361-10, Lot Number 12C1847), LDL (Cat No. 360-10, Lot Number 03C1863), and VLDL (Cat No. 365-10, Lot Number 11C1054) standards were purchased from Lee Biosolutions.

Techniques:

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Hepatitis C virus utilizes VLDLR as a novel entry pathway

doi: 10.1073/pnas.1506524113

Figure Lengend Snippet: Effect of HCV E2 and ApoE on VLDLR-mediated HCV entry. (A) Huh7.5 or Huh7 cells transfected with a VLDLR-expressing plasmid were preincubated with IgG as a control or with anti-VLDLR for 1 h at 37 °C. (B and C) After treatment, the cells were infected with Luc-HCVccJFH1 (MOI = 0.1) for 48 h (average ± SD; n = 3). Luc-HCVccJFH1 was preincubated with an IgG control or anti-ApoE (B) and anti-HCV E2 (C). Huh7.5 or Huh7 cells transfected with a VLDLR-expressing plasmid were infected with antibody-treated Luc-HCVccJFH1 (MOI = 0.1) for 48 h (average ± SD; n = 3). (D) Recombinant VLDLR-coated plates were reacted with purified HCV E2 or with purified HCV E2 treated with anti-E2 antibody. The signal was detected using an anti-FLAG antibody and HRP-conjugated mouse IgG. Light absorbance was measured at 450 nm (average ± SD; n = 3). The data shown represent three independent experiments. *P < 0.05, ***P < 0.005 (Student’s t-test).

Article Snippet: Recombinant human VLDLR was purchased from Sino Biological.

Techniques: Transfection, Expressing, Plasmid Preparation, Infection, Recombinant, Purification

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Hepatitis C virus utilizes VLDLR as a novel entry pathway

doi: 10.1073/pnas.1506524113

Figure Lengend Snippet: Mouse VLDLR promotes HCV entry. (A) VLDLR expression was analyzed by RT-PCR using cDNAs from human and mouse liver tissue. G3PDH was used as an internal control. (B) Huh7.5 #26 cells transfected with empty or mouse VLDLR-expressing plasmid were infected with HCVccJFH1 (MOI = 1). The cells were stained with NS5A (red) and VLDLR (6A6) (green) antibodies 48 h postinfection. The images were analyzed by confocal microscopy. (Scale bars, 20 μm.) (C) Hepa1-6 cells (mouse hepatocytes) transfected with an empty vector, a human VLDLR-expressing plasmid, or a mouse VLDLR-expressing plasmid were infected with Luc-VSV-Gpp or Luc-HCVpp (2a). The luciferase activity was analyzed 72 h postinfection (average ± SD; n = 3). (D) Human and mouse VLDLR expression in Hepa1-6 cells was assessed by immunoblotting. The data shown represent three independent experiments. ***P < 0.005 (Student’s t-test).

Article Snippet: Recombinant human VLDLR was purchased from Sino Biological.

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Transfection, Plasmid Preparation, Infection, Staining, Confocal Microscopy, Luciferase, Activity Assay, Western Blot

Journal: Journal of Extracellular Vesicles

Article Title: Prospects and limitations of antibody-mediated clearing of lipoproteins from blood plasma prior to nanoparticle tracking analysis of extracellular vesicles

doi: 10.1080/20013078.2017.1308779

Figure Lengend Snippet: Effect of application of the bead procedure on particles in (a) VLDL (1 mg of protein per mL) and (b) LDL (5 mg of protein per mL) isolates from a commercial source. Prior to measurement and application of the bead procedure the isolates were diluted to obtain particle concentrations within the linear range of NTA as specified in the materials and methods section.

Article Snippet: As controls were used solutions with human Low Density Lipoprotein (LDL) 5 mg/mL and Human Very Low Density Lipoprotein (VLDL) 1 mg/mL (Kalen Biomedical, Montgomery Village, MD, USA).

Techniques:

Journal: Journal of Extracellular Vesicles

Article Title: Prospects and limitations of antibody-mediated clearing of lipoproteins from blood plasma prior to nanoparticle tracking analysis of extracellular vesicles

doi: 10.1080/20013078.2017.1308779

Figure Lengend Snippet: (a) Effect of bead procedure on apolipoprotein B content in PFP ( n = 4) and lipoprotein isolates from a commercial source. Lines combine levels measured before (open circles) and after (closed circles) application of the bead procedure on PFP samples from four healthy persons (empty ‘before beads’ circles), diluted VLDL isolate (‘before beads’ circle with dot), and diluted LDL isolate (‘before beads’ circle with cross). (b) Effect of bead procedure on EV content measured as relative fluorescence intensity by EV array in PFP ( n = 4). Lines combine levels measured before (open circles) and after (closed circles) application of the bead procedure on PFP samples from four healthy persons.

Article Snippet: As controls were used solutions with human Low Density Lipoprotein (LDL) 5 mg/mL and Human Very Low Density Lipoprotein (VLDL) 1 mg/mL (Kalen Biomedical, Montgomery Village, MD, USA).

Techniques: Fluorescence